The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward for early diagnosis.

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...

Ammon News - The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's ...